Articles

The National Cancer Institute (NCI) defines cancer survivors as “people who have been diagnosed with cancer and the people in their lives who are affected by their diagnosis including family members, friends, and caregivers.”

Read More ›

Americans afflicted with cancer are living longer, and the outlook for them continues to improve. On the strength of public awareness, early detection, and improved multimodal cancer treatment, cancer has evolved for many patients from an often fatal disease to a chronic, treatable condition. Read More ›


Over the past three decades, there has been a gradual yet steady increase in survivorship awareness, resources, and services. Although none of this has happened easily or rapidly, there is no doubt that the concept of cancer survivorship is here to stay. Read More ›


Women with ductal carcinoma in situ (DCIS) who have mammographically dense breasts may be at increased risk for subsequent breast cancer, especially in the contralateral breast, researchers at Kaiser Permanente report.
 
Read More ›

A study of men with a family history of breast cancer revealed that nearly 80% were unaware of their own risk for breast cancer, and all of them said that their healthcare provider had not discussed the disease with them.
 
Read More ›

Although commonly referred to as “chemobrain” and described most often in women with breast cancer, cognitive impairments may occur in patients with other types of cancer and after hormonal and radiation therapies as well, a new study suggests. Another recent study was the first to use imaging to show changes in brain tissue in women undergoing chemotherapy.
 
Read More ›

Preliminary results of an ongoing trial suggest that a combination of trastuzumab, bevacizumab, and docetaxel is safe and effective as first-line therapy in women with metastatic breast cancer (MBC).
 
Fourteen of the 18 patients treated to date had a partial response or stable disease, a clinical benefit rate of 77.7, the investigators report.
 
Read More ›

Adding the monoclonal antibody rituximab to chemotherapy signicantly increases both progression-free and overall survival in previously untreated patients with chronic lymphocytic leukemia (CLL), the German Lymphocytic Leukemia Study Group reports.
 
Read More ›

The recently approved taxane cabazitaxel significantly improved overall survival in men with castration-resistant prostate cancer in a multinational phase 3 study.
 
The TROPIC investigators found that men treated with cabazitaxel plus prednisone had 30% lower risk of death compared with patients treated with mitoxantrone plus prednisone.
 
Read More ›

Results of a trial by the Children's Oncology Group indicate that children with intermediate-risk neuroblastoma can be successfully treated with a shorter duration and lower doses of chemotherapy than are currently used.
 
Findings from the phase 3 trial reported in the September 30, 2010, issue of the New England Journal of Medicine may change the approach to treating the disease, which affects 650 children in the United States each year.
 

 

Read More ›

Page 364 of 377


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: